Gilead Sciences, Inc. $GILD Shares Bought by Mission Wealth Management LP

Mission Wealth Management LP increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 46.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 16,879 shares of the biopharmaceutical company’s stock after purchasing an additional 5,320 shares during the quarter. Mission Wealth Management LP’s holdings in Gilead Sciences were worth $2,132,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at about $215,000. Sivia Capital Partners LLC grew its position in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 602 shares during the last quarter. Ieq Capital LLC increased its stake in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after purchasing an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC lifted its holdings in Gilead Sciences by 18.6% in the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after purchasing an additional 674 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, HSBC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 82,000 shares of company stock valued at $10,641,790. Insiders own 0.30% of the company’s stock.

Gilead Sciences Trading Up 0.1%

GILD opened at $135.87 on Thursday. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The firm’s fifty day moving average is $129.75 and its two-hundred day moving average is $136.42. The firm has a market cap of $168.47 billion, a PE ratio of -50.89 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.01 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences’s payout ratio is presently -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.